Zephyrnet Logo

Tag: Breakthrough Device Designation

Endogenex™ Announces $88 Million Series C Financing to Complete Pivotal Trial of the ReCET™ System in Patients with Type 2 Diabetes | BioSpace

Oversubscribed financing led by strategic investor, with participation from new and existing investors MINNEAPOLIS, June 25, 2024 /PRNewswire/ -- Endogenex, a clinical-stage medical device company...

Top News

Helsinki-based Sooma secures €5 million to brain stimulate yourself out of depression from home | EU-Startups

Sooma Medical, a leading provider of effective brain stimulation treatments for psychiatric and neurological disorders, announced its new growth funding of €5 million. The...

ONWARD® Medical Accepted to New US FDA TAP Program for Development of its ARC-BCI™ System | BioSpace

The Company is one of the first brain-computer interface entrants accepted into this program, intended to optimize the commercialization pathway for breakthrough medical technology EINDHOVEN,...

Curavit Successfully Completes a Virtual Clinical Trial for Sana’s Investigative Digital Therapeutic to Treat Symptoms of PTSD | BioSpace

NEW YORK, Feb. 12, 2024 /PRNewswire/ -- Curavit Clinical Research, a virtual contract research organization (VCRO) that specializes in decentralized clinical trials (DCTs) for...

CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer | BioSpace

Appointment effective February 12 following Nadim Yared’s retirement Hykes currently serves as Augmedics’ President and CEO, and has served on CVRx’s Board of Directors...

Latest Intelligence

spot_img
spot_img